BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.EBI
University of Lille
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.EBI
Glaxosmithkline
Phage-encoded combinatorial chemical libraries based on bicyclic peptides.EBI
Laboratory of Molecular Biology, Medical Research Council
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.EBI
Glaxosmithkline
The evolution of small molecule enzyme activators.EBI
University of Nebraska
Structure-Guided Chemical Optimization of Bicyclic Peptide (EBI
Bicycletx
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.EBI
Qufu Normal University
Thorectidiol A Isolated from the Marine Sponge EBI
University of British Columbia
Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.EBI
Shandong University
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.EBI
American University of Ras Al Khaimah
Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection.EBI
Kingston University
Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.EBI
Zhengzhou University
Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein.EBI
University of Groningen
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.EBI
University of California San Francisco (Ucsf)
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.EBI
Qpex Biopharma
The Other Angiotensin II Receptor: ATEBI
Centre Hospitalier Universitaire Vaudois (Chuv) and University of Lausanne (Unil
 
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19BDB
Pfizer
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.BDB
University of Illinois At Chicago
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.BDB
University of Bonn
Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.BDB
Millennium Pharmaceuticals
Development of Potent and Selective Phosphinic Peptide Inhibitors of Angiotensin-Converting Enzyme 2.BDB
University of Athens